Abstract
Gene expression modulator 91 [GEM-91; Hybridon] and anti-HIV ribozymes are emerging as potential agents for combatting HIV infection. The first US phase I study with GEM-91 in patients infected with HIV has now been completed. In addition, research with anti-HIV-1 ribozymes has taken a step forward with the development of a novel ribozyme delivery strategy. The progress with these agents was discussed at the IIR Ltd conference, entitled‘Antisense Therapy: Efficacy and Delivery of Antisense & Ribozyme Oligonucleotides’[London, UK; February 1995].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
